Resilience (National Resilience) Stock
| Valuation | $8.84B1 |
| Valuation Date | Jun 6, 2022 |
| Implied Valuation | n/a |
| Last Price | $11.04 |
| 52-Week High | $11.04 |
| 52-Week Low | $11.04 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $2.28B2, 3 |
| Latest Round Amount | $625M2 |
| Latest Round | Series D |
| Funding Rounds | 6 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Resilience
Resilience is a contract development and manufacturing organization that manufactures complex medicines for biopharmaceutical partners. It provides biologics drug substance manufacturing, cell therapy production and aseptic fill-finish for injectable drugs, along with device assembly and packaging. Resilience makes money by charging biopharma companies for development and manufacturing services from clinical through commercial scale.
Invest in Resilience
Resilience is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
News
Lilly, Resilience to invest $750 million in US drug manufacturing expansion
Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine supp...
Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Eli Lilly said they are investing $750 million to expand Resilience's Cincinnati-area manufacturing, including production of Lilly's KwikPen injectable device for diabetes and obesity m...
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 (GLOBE NEWSWIRE) -- Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today announced the relocation of Resilience's ...
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
Resilience relocated its corporate headquarters from San Diego to Blue Ash, Ohio, and said it would expand sterile manufacturing and packaging capabilities near its West Chester drug product site.
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
National Resilience secured up to $825 million in long-term debt financing from Oak Hill Advisors to strengthen its balance sheet and invest in go-forward manufacturing operations anchored in Cincinna...
.png)
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
Resilience announced long-term debt financing of up to $825 million from Oak Hill Advisors, including a $600 million first-lien commitment with an initial $525 million tranche, to fund Cincinnati and ...
National Resilience, a well-funded manufacturing startup, to scale back operations
Resilience said it would wind down six underutilized plants in California, Massachusetts and Florida after capacity growth outpaced demand, while focusing on Cincinnati and Toronto and raising $250 mi...
National Resilience will close 6 of its 10 plants and carry on as streamlined CDMO
Fierce Pharma reported Resilience is closing six of about ten plants through a leaseholder affiliate's legal process while continuing operations at remaining hubs including Cincinnati and Toronto.
Resilience Provides Customers With Update on CDMO Business Strategy and Manufacturing Footprint
In a customer update, Resilience said existing institutional investors provided $250 million in bridge financing to support consolidating its manufacturing footprint and that it was pursuing additiona...
Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401
Resilience expanded its partnership with Parvus Therapeutics to support development and manufacturing of PVT401, a novel autoimmune drug candidate for inflammatory bowel disease.
Resilience Announces Appointment of William S. Marth, RPh., MBA as Chief Executive Officer
Resilience named William S. Marth, previously its president and COO, as president and CEO effective December 5, 2024.
Resilience Announces Equity Investment From Mubadala And Funding Of New Biopharma Manufacturing Facility In The United Arab Emirates
Resilience announced an equity investment from Mubadala paired with a plan for Mubadala to build a biopharma manufacturing facility in Abu Dhabi that Resilience would operate.
Resilience Announces $625 Million Series D Financing To Expand Network, Bring Innovative Technologies To Biomanufacturing
Resilience raised $625 million in Series D financing and disclosed a previously unannounced $600 million Series C from August 2021, saying it had secured more than $2 billion in equity since founding.
Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19
TechCrunch reported National Resilience launched with more than $800 million in financing from investors including ARCH Venture Partners and 8VC to remake biopharmaceutical manufacturing.